The HDHD5 Knockout Ca Ski Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the Ca Ski cervical carcinoma cell line, with targeted disruption of the HDHD5 gene. This pooled product provides a loss-of-function model without clonal selection, enabling robust assessment of HDHD5 function in a genetically diverse cellular background. The polyclonal format preserves the inherent heterogeneity of the parental line while introducing HDHD5 gene disruption across the population, making it suitable for experiments where averaged population responses are informative.
The Ca Ski host cell line is a widely used model of HPV16-positive cervical carcinoma, originally established from a cervical epidermoid carcinoma metastasis to the small intestine. These cells harbor integrated human papillomavirus type 16 (HPV16) DNA and constitutively express the viral oncoproteins E6 and E7, which drive cellular transformation and maintain the malignant phenotype. Ca Ski cells are extensively employed to study HPV-related carcinogenesis, metastasis mechanisms, and therapeutic responses in a cervical cancer context. Their epithelial origin and metastatic derivation make them particularly relevant for investigating tumor progression and metabolic adaptations in HPV-driven malignancies.
HDHD5 encodes a haloacid dehalogenase-type phosphatase that specifically hydrolyzes diphosphoinositol pentakisphosphate (IP7) to inositol hexakisphosphate (IP6). This enzymatic activity positions HDHD5 as a critical regulator of intracellular IP6/IP7 balance, linking inositol phosphate metabolism to energy sensing and phosphate homeostasis. HDHD5 is modulated by upstream metabolic signals, including the AMP:ATP ratio and nutrient deprivation, and its activity influences downstream phosphate-responsive signaling cascades and glycolytic flux. It operates within a network involving interacting factors such as IP6, IP7, IP6 kinases (IP6K), IP7 kinases (IP7K), and regulatory enzymes like PPIP5K and DIPP. Disruption of HDHD5 is expected to perturb the catabolism of IP7, leading to accumulation of this high-energy metabolite and potential alterations in cellular energetics and phosphate-regulated processes.
In the Ca Ski cervical carcinoma background, loss of HDHD5 function provides a powerful tool to dissect the interplay between inositol pyrophosphate signaling and HPV-driven oncogenesis. HPV16 E6 and E7 oncoproteins reprogram host cell metabolism to support proliferation and survival; perturbing HDHD5-mediated IP7 hydrolysis can potentially amplify or counteract these metabolic rewiring effects. This knockout model may reveal novel vulnerabilities in HPV-positive cancer cells related to phosphate-associated energy metabolism, offering insights into how cervical cancer cells manage metabolic stress. Moreover, studying HDHD5 disruption in this context could highlight synthetic lethal interactions or metabolic dependencies that may be exploited therapeutically.
Researchers can employ these polyclonal knockout cells in a variety of assays to investigate HDHD5 function and the wider inositol pyrophosphate pathway. Typical applications include measuring IP7/IP6 ratios by LC-MS to confirm metabolic changes, assessing phosphate uptake kinetics, and evaluating glycolytic and mitochondrial respiration using Seahorse analyzers. Functional assays such as MTT proliferation, wound healing migration, and Boyden chamber invasion studies can delineate the impact on tumorigenic properties. Concurrent analyses of HPV16 E6/E7 expression via RT-qPCR and western blotting for HDHD5 allow correlation of viral oncoprotein levels with metabolic phenotypes. These cells are also suited for small-molecule screening aimed at identifying modulators of phosphate metabolism or cervical cancer cell proliferation. For additional details about this product, please contact Ascent Research.
